However, patients with TP53-mutated AML and MDS exhibit significantly lower response rates to conventional therapies, including cytotoxic chemotherapy, hypomethylating agents (HMAs) such as azacitidine and decitabine, and venetoclax-based regimens. This evidence concerns the gene TP53 and myelodysplastic syndrome.